|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by educational grants from
Arcutis Biotherapeutics and Bristol Myers Squibb
Description:
Psoriasis is a complex, chronic, immune-mediated inflammatory
disease that affects approximately 7 million of the population in
the United States. Psoriasis is a periodic flare-up of sharply
defined red patches, covered by a silvery, flaky surface. The main
disease activity leading to psoriasis occurs in the epidermis, the
top five layers of the skin. The disease most commonly appears on
the skin of the scalp, elbow, knees, and lumbosacral areas of the
body. Many of the patients are not receiving the appropriate
treatment discussed in the current guidelines and standards of care.
Psoriasis is a complex disease to manage, but the goal should be a
patient-centered treatment that reduces disease burden, improves on
quality-of-life, and addresses the risks of systemic complications
and comorbid conditions. The under diagnosis and treatment of
psoriasis continues to be a serious concern.
Upon completion of this
activity, participants will be able to:
-
Discuss the latest developments in
the treatment and management of psoriasis, including a close
look at new data and guidelines recommendations
-
Explore diagnostic updates of
various stages of psoriasis and how this relates to both drug
development and use of traditional and modern therapeutic
options
-
Assess key clinical trial data for
novel and emerging therapies intended to improve symptoms, and
slow or prevent progression of psoriasis
-
Discuss personalized treatment plans
for psoriasis by using patient-provider shared decision-making
opportunities
|
Faculty: |
Paul Yamauchi, MD, PhD
Clinical Assistant Professor of Dermatology
David Geffen School of Medicine at UCLA
Adjunct Associate Professor, John Wayne Cancer Institute |
|
Disclosure:
|
(Relevant
Financial Relationships with Ineligible Companies in the
Last 24 Months):
Dr. Yamauchi has served on an advisory board for Amgen,
ChemoCentryx, Dermira, and Lilly. He has served as a
consultant for AbbVie, Amgen, Arcutis, Inc, Celgene,
Dermavant Sciences, Janssen, Leo Pharma, Menlo
Therapeutics, Novartis, Ortho Dermatologics, Pfizer,
Regeneron, Sun Pharmaceuticals, and UCB. He has received
grant/research support from AbbVie, Akros, Amgen,
AnaptysBio, Arcutis, Inc, Boehringer Ingelheim, Botanix
Pharmaceuticals, Bristol Myers Squibb, Celgene,
Dermavant, Dermira, Escalier, Galderma, Galapagos,
Genentech, Glenmark, Hovione, Incyte, Janssen, Kiniksa,
Leo Pharma, Lilly, MedImmune, Menlo Therapeutics,
Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sandoz,
Sol-Gel Technologies, Sun Pharmaceuticals, UCB, and
Vanda. He has served on the speaker's bureau for AbbVie,
Almirall, Amgen, Celgene, Dermira, Janssen, Leo Pharma,
Lilly, Novartis, Ortho Dermatologics, Pfizer, Regeneron,
Sanofi, Sun Pharmaceuticals, and UCB. His presentation
has been reviewed for any bias. |
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by
educational grants from
Arcutis Biotherapeutics and Bristol Myers Squibb
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |